Bumrungrad Hospital (BH) Q3 2026 (Q&A) earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 (Q&A) earnings summary
12 Nov, 2026Executive summary
Q3 2026 consolidated revenue was Baht 6,726,511 thousand, operating profit Baht 2,509,222 thousand and net profit Baht 2,078,062 thousand; 9M net profit reached Baht 5,788,378 thousand.
9M consolidated operating cash flow was Baht 6,978,178 thousand; cash and cash equivalents stood at Baht 5,422,054 thousand at 30 September 2026.
Financial highlights
Q3 hospital-operation revenue was Baht 6,676,471 thousand versus Baht 6,491,974 thousand in Q3 2025; total revenue was Baht 6,726,511 thousand versus Baht 6,581,502 thousand.
Q3 operating profit was Baht 2,509,222 thousand versus Baht 2,461,675 thousand; net profit was Baht 2,078,062 thousand versus Baht 2,046,719 thousand.
9M total revenue was Baht 19,253,116 thousand versus Baht 18,890,293 thousand; operating profit was Baht 6,990,229 thousand versus Baht 6,822,775 thousand.
9M net profit was Baht 5,788,378 thousand versus Baht 5,670,115 thousand; profit attributable to equity holders was Baht 5,744,051 thousand versus Baht 5,626,417 thousand.
Key financial ratios and metrics
Q3 basic EPS was Baht 2.60 versus Baht 2.56; diluted EPS was Baht 2.38 versus Baht 2.35.
9M basic EPS was Baht 7.23 versus Baht 7.08; diluted EPS was Baht 6.62 versus Baht 6.49.
Latest events from Bumrungrad Hospital
- Revenue and profit advanced, alongside higher overdue receivables and major investment commitments.BH
Q3 2026 Pre recorded - Record FY2023 earnings, led by international patients and strong insurance growth.BH
Q4 2023 - Q2 2026 revenue and profit rose on strong international demand; margins and dividends remained high.BH
Q2 2026 - Q1 2026 saw revenue and profit growth, strong margins, and rising international patient revenue.BH
Q1 2026 (Q&A) - Record EBITDA margin and strong international patient growth drove Q1 2026 results.BH
Q1 2026 Pre-recorded - Record EBITDA margin and special dividend highlight a resilient Q4 amid international growth.BH
Q4 2025 - Q3 2025 delivered record margins and profit, led by international patient growth and expansion.BH
Q3 2025 - Record profit growth and margins in Q2 and H1 2024, with a record interim dividend declared.BH
Q2 2024 - EPS and net profit rose 11% in 2024, with record margins and a proposed record dividend.BH
Q4 2024